# Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention

Study · id `cardio:ct-nct05241431` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05241431](<https://clinicaltrials.gov/study/NCT05241431>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05241431

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 106 participants.

## Technical summary

Registry record NCT05241431. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-12 (actual); primary completion 2024-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 106 participants (planned count; ClinicalTrials.gov record NCT05241431, source copy `cardio:ctgov-nct05241431-2022-02-15`, retrieved 2026-10-26)
- Started: 2022-02-12 (actual) (ClinicalTrials.gov record NCT05241431, source copy `cardio:ctgov-nct05241431-2022-02-15`, retrieved 2026-10-26)
- Primary completion: 2024-03-01 (anticipated) (ClinicalTrials.gov record NCT05241431, source copy `cardio:ctgov-nct05241431-2022-02-15`, retrieved 2026-10-26)
- Completion: 2024-04-01 (anticipated) (ClinicalTrials.gov record NCT05241431, source copy `cardio:ctgov-nct05241431-2022-02-15`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT05241431, source copy `cardio:ctgov-nct05241431-2022-02-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05241431-2022-02-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
- Acronym: DAPAS
- Condition: Aortic Stenosis
- Condition: Left Ventricle Hypertrophied
- Intervention (Drug): SGLT2 inhibitor
- Intervention (Drug): Placebo
- Lead sponsor: University of Aarhus
- Lead sponsor class: OTHER
- Collaborator: Aarhus University Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: University of Aarhus (`cardio:org-university-of-aarhus`)
- Registry lists this organization as a collaborator: Aarhus University Hospital (`cardio:org-aarhus-university-hospital`)

## Provenance

Content hash: 21b35158948c27816869797b76c070a6c312ae36aa5267f1d64d5de904b66881
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
